Our mission
To transform the treatment of severe diseases by integrating multiplex gene editing, hypoimmunity engineering, and targeted in vivo delivery, unlocking universally accessible cell therapies.
Explore our technology
Our story
Bringing genome engineering to cell and organ therapies
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies.
Mission & vision
Our vision
A world where cell and organ therapies are universally available to patients.
Company milestones
Visit the newsroomQihan Biotech is founded
Luhan Yang and George Church co-found Qihan to apply genome engineering to cell and organ therapies.
Cell publishes CAR-NK clinical findings
The publication reports findings from research into an investigational iPSC-derived cell therapy for systemic sclerosis.
Browse scientific publicationsDosing begins in a Phase I/IIa trial
Qihan announces first dosing in a study evaluating its investigational allogeneic CAR-T therapy for refractory lupus.
View QT-019B in the pipelineQT-019B receives two FDA designations
Qihan announces Regenerative Medicine Advanced Therapy designation and Breakthrough Therapy Designation for QT-019B.
